<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02372955</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-14-10022/D1690L00020</org_study_id>
    <nct_id>NCT02372955</nct_id>
  </id_info>
  <brief_title>Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes</brief_title>
  <official_title>Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gulf Regional Research &amp; Educational Services, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gulf Regional Research &amp; Educational Services, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dapagliflozin has been shown to lower clinic systolic and diastolic blood pressure in&#xD;
      patients with type 2 diabetes mellitus. The exact mechanism(s) by which dapagliflozin lowers&#xD;
      clinic SBP is unknown. The primary objective of the study is to determine the effect of&#xD;
      dapagliflozin , 10 mg daily, on parameters of arterial stiffness: aPWV, augmentation index&#xD;
      (AI), 24-hour blood pressure patterns, SBP, and pulse pressure. Urinary sodium excretion, and&#xD;
      Intravascular volume status will be recorded. The study will involve 21 subjects for a&#xD;
      duration of 16 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dapagliflozin has been shown to lower clinic systolic and diastolic blood pressure in&#xD;
      patients with type 2 diabetes mellitus. In particular, the reduction in SBP is impressive.&#xD;
      The effect on circadian patterns of blood pressure measured by ambulatory blood pressure&#xD;
      monitoring has not been established. The exact mechanism(s) by which dapagliflozin lowers&#xD;
      clinic SBP is not clear although there has been speculation that it is due to a decrease in&#xD;
      intravascular volume secondary to the osmotic diuresis produced by the drug. However, SBP is&#xD;
      dependent on both pulse volume and vascular stiffness (impedance to ejection).&#xD;
&#xD;
      Dapagliflozin may have a favorable effect on vascular stiffness by a reduction in blood&#xD;
      glucose resulting in decreased proximal arterial collagen cross-linking due to non-enzymatic&#xD;
      glycosylation of proteins.&#xD;
&#xD;
      Dapagliflozin may also have a favorable effect on vascular stiffness by increasing urinary&#xD;
      sodium excretion. Dapagliflozin is a sodium/glucose co-transporter inhibitor and the effects&#xD;
      on sodium excretion are not clear. Increased sodium intake is associated with an increase in&#xD;
      vascular stiffness.&#xD;
&#xD;
      An increase in vascular stiffness has been correlated with increased cardiovascular morbidity&#xD;
      and mortality. Thus, it is important to know if dapagliflozin has an effect on vascular&#xD;
      stiffness.&#xD;
&#xD;
      The current &quot;gold standard&quot; for vascular stiffness is aortic pulse wave velocity (aPWV).&#xD;
      Other measures of vascular stiffness include: systolic blood pressure, pulse pressure and&#xD;
      augmentation index. Also, measurement of calculated central blood pressure provides&#xD;
      information that may not be apparent from measurement of brachial blood pressure.&#xD;
&#xD;
      Measures of intravascular volume status include: body weight, jugular venous pressure,&#xD;
      orthostatic changes in blood pressure and heart rate.&#xD;
&#xD;
      It is important to recognize that some oral anti-diabetic drugs, e.g. sulfonylurea's are&#xD;
      associated with an increase in systemic arterial blood pressure.&#xD;
&#xD;
      Hypothesis&#xD;
&#xD;
      That treatment of type 2 diabetes mellitus with dapagliflozin will result in a decrease in&#xD;
      arterial stiffness&#xD;
&#xD;
      Primary Objectives&#xD;
&#xD;
      The primary objective of the study is to determine the effect of dapagliflozin (Appendix A),&#xD;
      10 mg daily, on parameters of arterial stiffness: aPWV, augmentation index (AI), 24-hour&#xD;
      blood pressure patterns, SBP, and pulse pressure.&#xD;
&#xD;
      Key Questions&#xD;
&#xD;
        -  What effect will dapagliflozin have on measures of arterial stiffness?&#xD;
&#xD;
        -  What effect will dapagliflozin have on central blood pressure?&#xD;
&#xD;
        -  Will dapagliflozin lower BP over the 24-hour period and will the pattern of BP change?&#xD;
&#xD;
        -  Will dapagliflozin increase sodium excretion for 16 weeks?&#xD;
&#xD;
        -  What will be the effect of dapagliflozin on intravascular volume status at 16 weeks?&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        -  Urinary sodium excretion&#xD;
&#xD;
        -  Intravascular volume status: jugular venous pressure, body weight, orthostatic change in&#xD;
           BP and pulse rate&#xD;
&#xD;
      Treatment&#xD;
&#xD;
      All patients will receive a background treatment with metformin. After randomization (2:1)&#xD;
      patients will receive dapagliflozin, 10 mg daily or glimpiride (Appendix B), 4 mg daily. The&#xD;
      treatment period will last ;16 weeks.&#xD;
&#xD;
      For high risk subjects, dapagliflozin therapy will begin with 5 mg with up-titration at 2&#xD;
      weeks. High risk subjects are those prone to volume depletion and are identified by signs of&#xD;
      hypovolemia, e.g. low venous pressure, and a low arteriasl blood pressure.&#xD;
&#xD;
      Subjects will also be closely monitored for the development of hypoglycemia. This risk will&#xD;
      be minimized by not enrolling subjects taking insulin. Subjects will be made aware of the&#xD;
      signs of hypotlycemia, e.g. sweating and palpitation, and will be instructed to treat with&#xD;
      ingestion of sugar, particularly fructose in orange juice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>systolic blood pressure by ambulatory blood pressure monitoring (ABPM)</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>arterial stiffness</measure>
    <time_frame>16 weeks</time_frame>
    <description>arterial stiffness will be assessed by measuring aortic pulse wave velocity (aPWV) and augmentation index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>urinary sodium excretion</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite intravascular volume status</measure>
    <time_frame>16 weeks</time_frame>
    <description>jugular venous pressure, body weight, orthostatic change in BP and pulse rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>dapagliflozin 10 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dapagliflozin, 10 mg daily for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glimpiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>glimpiride 4 mg daily for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin</intervention_name>
    <description>subjects will be randomly assigned to receive dapagliflozin 10 mg daily</description>
    <arm_group_label>dapagliflozin 10 mg daily</arm_group_label>
    <other_name>Farxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimpiride</intervention_name>
    <description>subjects will be randomly assigned to receive glimpiride 4 mg daily</description>
    <arm_group_label>glimpiride</arm_group_label>
    <other_name>Amaryl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes mellitus&#xD;
&#xD;
          -  Metformin treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  â€¢ Type 1 diabetes mellitus&#xD;
&#xD;
               -  Hgb A1c &gt; 9&#xD;
&#xD;
               -  Advanced diabetic complications, e.g. diabetic renal disease (eGFR &lt; 60 cc/min),&#xD;
                  heavy proteinuria, diabetic retinopathy, autonomic neuropathy&#xD;
&#xD;
               -  Pregnancy or unwilling to practice contraception.&#xD;
&#xD;
               -  Uncontrolled hypertension (SBP &gt; 150 mm Hg; DBP &gt; 100 mm Hg)&#xD;
&#xD;
               -  Chronic substance abusers&#xD;
&#xD;
               -  Carcinoma of the urinary bladder&#xD;
&#xD;
               -  Subjects deemed at risk for dehydration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas D Giles, MD</last_name>
    <phone>504.834.8668</phone>
    <email>tgiles4@cox.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louise E Roffidal, BSN, MPH</last_name>
    <phone>504.220.6275</phone>
    <email>lroffidal.grres@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gulf Regional Research &amp; Educational Services, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas D Giles, MD</last_name>
      <phone>504-834-8668</phone>
      <email>tgiles4@cox.net</email>
    </contact>
    <contact_backup>
      <last_name>Louise E Roffidal, BSN, MPH</last_name>
      <phone>504.220.6275</phone>
      <email>lroffidal.grres@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>January 7, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <last_update_submitted>February 20, 2015</last_update_submitted>
  <last_update_submitted_qc>February 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gulf Regional Research &amp; Educational Services, LLC</investigator_affiliation>
    <investigator_full_name>Thomas Giles</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

